Pharmaceutical Market Still In Favour Of Patented Medicines

Mexico's pharmaceutical market comprised US$7.9bn worth of patented medicines and US$1.49bn worth of OTC drugs by the end of 2009. BMI believes that growth is still promising in the prescription drug market, with dominant players like Eli Lilly launching new marketing campaigns to boost sales in key therapeutic areas, including diabetes and oncology. However, we also caution that the January 2010 Supreme Court ruling to allow second-use patents warrants an updated analysis of Mexico's pharmaceutical market.

To read the full article, please choose one of the following options: